

- Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipodystrophy; *Diabetes*; (2000); 49: 1958-62.
- [13] Garg, A.; Acquired and inherited lipodystrophies ; *N. Engl. J Med*; 350 (2004) ;(12): 1220-34.
- [14] World Health Organization; Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. Geneva (2000).
- [15] Brown W.V., "High density lipoprotein and transport of 4- cholesterol and triglyceride in blood", *J. Clinical lipidology*, 2007; 1:p7-19.
- [16] Dobiasova M., Atherogenic index of plasma 7- [log(triglyceride/HDL-C-Colesterol)]: Theoretical and practical implications", *Clin. Chem.*, 2004; pp: 1113-5.
- [17] Susanti, E., Donosepoetro, M., Patellong, I., and Arif, 8-M., "Differences between several atherogenic parameters in patients with controlled and uncontrolled type 2 Diabetes Mellitus *Med. J. Indones*, 2010); 19(2): 103-108.
- [18] Fiancis, S.; Green span, David, G.; Garduer; Basic and clinical endocrinology; 6th ed.; chapter 20; disorder of lipoprotein metabolic: Mary, J.; malloy, M.D.; John, P.; Kane, M.D. ;(2001): 7230.
- [19] Dobiasova, M., Frohlich, J. "The plasma parameter log (TG/HDL-C) as atherogenic index; correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FERHDL)". *ClinBiochem.*, (2001).34: 583-588.
- [20] Brehm, A., Pfeiler, G., Pacini, G., Vierhapper, H., and Roden, M. "Relationship between Serum Lipoprotein Ratios and Insulin Resistance in Obesity". *Clin. Chem.*;(2004). 50:2316-2322.
- [21] Wallace, T.M.; Levy, J.C. & Matthews, D.R.; Use and abuse of HOMA modeling.; *Diabetes Care*; (2004); 27 (6): 1487-95
- [22] Al-Tai W., Jaffer E. and Ali Z., Evaluating the utility of plasma Atherogenic Index among several Atherogenic parameters in patients with chronic renal failure on maintenance hemodialysis. *J Fac Med Baghdad.*, (2012); Vol.54, No.3:295-962
- [23] Grover, S.A., Levington, C., and Panquest S. "Identifying adults at low risk for significant hyperlipidemia: a validated clinical index", *J. Clin. Epidemiol.*, 1999;52:49-55.
- [24] Dobiasova, M., and Frohlich, J.: "The plasma parameter log (TG/HDL-C-C) as an atherogenic index", *ClinBiochem.*, (2001); 34:583-8
- [25] J. Geohas, A. Daly, and V. Juturu, "Chromium picolinate and biotin combination reduces atherogenic index of plasma in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial," *Am J Med Sci.*, (2007), 333, pp. 145-153.
- [26] E. George, "Differential Effect of Hormone Therapy and Tibolone on Lipids, Lipoproteins, and the Atherogenic Index of Plasma Christodoulakos," *Journal of Cardiovascular Pharmacology.*, (2006), Vol. 47, no.4, pp. 542-548.